FeesSafety
Pluang+

European Commission approves Amneal's biosimilar Adcomfo to XOLAIR for allergic asthma and other conditions

Market News
17 Nov 2026, 23:05 WIB
GlobeNewsWire
View Source
Bullish
European Commission approves Amneal's biosimilar Adcomfo to XOLAIR for allergic asthma and other conditions

Amneal Pharmaceuticals received European Commission approval for Adcomfo (omalizumab), a biosimilar to XOLAIR, expanding its availability across Europe after prior UK authorization. Adcomfo treats severe allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticaria, supported by clinical trials demonstrating comparable efficacy and safety to XOLAIR. The approval marks a significant step in Amneal's biosimilars portfolio growth, with the U.S. FDA currently reviewing its application for the same biosimilar. This broadens patient access to affordable biologic treatments in multiple markets.

Amneal Pharmaceuticals Inc. Class A stock trades at USD 21.12 on Pluang, down 0.52% as of Nov 18, 2026 04:21 WIB. This slight dip comes despite the positive news of European Commission approval for its biosimilar Adcomfo, which could expand Amneal's market presence. The stock's market cap stands at $7.40 billion, reflecting significant investor interest in the health sector company.

More News (AMRX)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App